Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Acerta Pharma BV

Home Clinical Trial Sponsors and OrganizationsAcerta Pharma BV

Acerta Pharma BV

ACTIVE

Netherlandswww.acerta-pharma.comSubsidiary

Part of 阿斯利康

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

108

75 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

76

70.4%

Phase 2

14

13.0%

Phase 3

10

9.3%

Not Applicable

2

1.9%

Trial Status Distribution

Active, not recruiting

73

67.6%

Completed

26

24.1%

Not yet recruiting

2

1.9%

Recruiting

3

2.8%

Terminated

3

2.8%

Withdrawn

1

0.9%

Clinical Trials

Trials sponsored by this organization (108)

A Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects <=65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma.

Active, not recruiting

Aug 2021600 participants

This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with already marketed drugs called Venetoclax and Obinutzumab in comparison to chemotherapy that is already in wide use for treatment of patients who have chronic lymphocytic leukemia and who have never been treated before.

Active, not recruiting

Jun 2021780 participants

A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study ofObinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with PreviouslyUntreated Chronic Lymphocytic Leukemia

Active, not recruiting

Jun 2021510 participants

A study of Acalabrutinib alone, or in combination with Rituximab and Lenalidomide for subjects with B-cell Non Hodgkin Lymphoma

Active, not recruiting

May 2021120 participants

A Trial to See the Effects of ACP-196 (the test drug) in Patients who have Mantle Cell Lymphoma

Active, not recruiting

Feb 2021117 participants

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Active, not recruiting

Jan 2021546 participants

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Active, not recruiting

Jan 2021500 participants

A Clinical trial to compare Acalabrutinib (ACP-196) versus investigator's choice standard treatment with Bendamustine/Rituximab or Idelalisib/Rituximab alone in patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Active, not recruiting

Jan 2021306 participants

Page 1 of 14

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials108
Approvals
News

Back to Organizations